No Data
Berry Genomics (000710.SZ): Plans to invest in the Fuzhou Xintou Zhi Kairui Kang Venture Capital Fund.
On December 30, Gelonghui reports that Berry Genomics (000710.SZ) announced that its wholly-owned subsidiary Fujian Berry Health and Technology Co., Ltd. (referred to as "Berry Health and Technology") has signed the "Fuzhou Xintou Zhikai Ruikang Venture Capital Fund Partnership Agreement (Limited Partnership)" with Shanghai Zhikai Asset Management Co., Ltd., Fuzhou Xintou Venture Capital Co., Ltd., Shanghai Runda Medical Technology Co., Ltd., and Shanghai Fukai Ruikang Enterprise Management Consulting Partnership (Limited Partnership). Together, they will invest to establish the Fuzhou Xintou Zhikai Ruikang Venture Capital Fund Partnership (Limited Partnership), with a fundraising target scale of.
Retail Investors Invested in Berry Genomics Co.,Ltd (SZSE:000710) up 12% Last Week, Insiders Too Were Rewarded
Berry Genomics (000710.SZ): Currently, there are no genetic drugs for liver diseases, nor are there any research and development of tumor genetic vaccines.
On December 3, BioMap (000710.SZ) stated on the investor interaction platform that the company currently does not have liver disease genetic drug products, nor does it have research and development of tumor genetic vaccines. The company is dedicated to fully converting gene sequencing technology into clinical applications, focusing on areas such as reproductive health, genetic disease testing, tumor detection, and technology services. The company currently provides sequencing services for some innovative drug companies.
Berry Genomics (000710.SZ): The controlling shareholder Gao Yang has cumulatively passively reduced their shareholding by 0.9997% of the company's shares.
On October 31, GeLongHui announced that berry genomics (000710.SZ) recently received a notification letter from its controlling shareholder, Mr. Gao Yang, regarding the expiration of the shareholding reduction plan: During the current passive shareholding reduction plan, Mr. Gao Yang has cumulatively passively reduced 3,534,149 shares of the company's stock, accounting for approximately 0.9997% of the total share capital of the company.
Berry Genomics: Q3 2024 Report
Berry Genomics (000710.SZ): The net income for the first three quarters was 10.3855 million yuan, an increase of 107.70% year-on-year.
On October 28th, Gelonhui announced Berry Genomics' (000710.SZ) third quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 0.823 billion yuan, a decrease of 4.96% year-on-year; net income attributable to shareholders of the listed company was 10.3855 million yuan, an increase of 107.70% year-on-year; net income after deducting non-recurring gains and losses was 12.8122 million yuan, an increase of 111.17% year-on-year; basic earnings per share were 0.0294 yuan/share.
We Think Berry GenomicsLtd (SZSE:000710) Has A Fair Chunk Of Debt
No Data
